Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering

Terje R Pedersen1, Ole Faergeman, John J P Kastelein

  • 1Center for Preventive Medicine, Ullevål University Hospital, N-0407 Oslo, Norway. t.r.pedersen@ioks.uio.no

The American Journal of Cardiology
|September 18, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026
Same author

Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling.

The journal of liquid biopsy·2025
Same author

Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC.

Clinical lung cancer·2024
Same author

Professor Jeremiah Stamler (1919-2022), "Father of Preventive Cardiology".

Atherosclerosis·2022
Same author

[Are triglyceride rich lipoproteins more dangerous than LDL cholesterol?]

Lakartidningen·2021
Same author

[Prevention of cardiovascular disease needs longer-term perspective].

Lakartidningen·2020

The IDEAL study compared atorvastatin with simvastatin in heart disease patients. Aggressive lipid lowering did not significantly reduce major coronary events, suggesting current statin therapy may be sufficient.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Coronary heart disease (CHD) management often involves statin therapy to lower low-density lipoprotein cholesterol (LDL-C).
  • The Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) study investigated if more intensive LDL-C reduction offers additional clinical benefits beyond standard statin treatment.

Purpose of the Study:

  • To determine if a strategy of more aggressive LDL-C lowering with high-dose atorvastatin provides greater clinical benefit than standard-dose simvastatin in patients with established CHD.
  • To assess the impact of intensive lipid lowering on major coronary events.

Main Methods:

  • A multicenter, prospective, randomized, open-label, blinded end-point classification study involving 8,888 patients post-myocardial infarction.

Related Experiment Videos

  • Patients were randomized to atorvastatin 80 mg/day or simvastatin 20 mg/day (escalated to 40 mg/day if needed).
  • Primary outcome: time to first major coronary event (nonfatal MI, coronary death, resuscitated cardiac arrest).

    • Main Results:

    • The study was powered to detect a 20% relative decrease in major coronary events with atorvastatin versus simvastatin over 5.5 years.
    • Baseline characteristics included a mean age of 61.7 years, with 19.1% women. Mean baseline LDL-C was 3.2 mmol/L (124 mg/dL).
    • A significant proportion of patients were already on statins (77%) and other cardiovascular medications prior to randomization.

    Conclusions:

    • The IDEAL study aimed to provide definitive evidence on the benefits of aggressive lipid lowering in CHD patients.
    • The trial design focused on a clinically relevant composite end point to evaluate treatment efficacy.
    • Results are anticipated to inform clinical guidelines regarding optimal statin therapy intensity for secondary prevention in patients with coronary heart disease.